Silver Book Fact

A prostate cancer vaccine, sipleucel-T immunotherapy, in men with metastatic castration-resistant prostate
cancer, reduced the risk of death by 22 percent compared to placebo, and represented a 4.2 month improvement in median survival.

Kantoff, P, C Higano, N Shore, E Berger, E Small, D Penson, et al. Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer. NEJM. 2010; 363: 411-22. http://www.nejm.org/doi/full/10.1056/NEJMoa1001294

Reference

Title
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
Publication
NEJM
Publication Date
2010
Authors
Kantoff, P, C Higano, N Shore, E Berger, E Small, D Penson, et al.
Pages
411-22
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Every additional dollar spent on overall breast cancer treatment has produced health gains valued at $4.80.  
  • The standard treatment for prostate cancer used to require radical prostatectomy. Now, less invasive therapies like brachytherapy have been shown to have equal outcomes with fewer side effects.  
  • The use of imatinib (Gleevec) has increased the eight-year survival rate for early chronic-phase myelogenous leukemia from 65% to 84%.  
  • In the U.S., new cancer drugs have increased life expectancy at birth by 10.7%.  
  • In 1971, one in 69 people was a cancer survivor (three million survivors). In 2014, that number grew to one in 22 people (14.5 million survivors).